Radiopharm Theranostics (ASX: RAD) has received approval from the Australian Ethics Committee for the inclusion of additional tumour...

Following publication of its findings in “Frontiers in Nuclear Medicine”, Radiopharm Theranostics (ASX: RAD) revealed a clinical study...

ASX-listed Radiopharm Theranostics (ASX: RAD) has teamed up with US-based BAMF Health to kick off phase 2b trials for its cancer...

ASX-listed Radiopharm Theranostics (ASX: RAD) has joined forces with a renowned global radiopharmaceutical manufacturer to produce its...

Radiopharm Theranostics (ASX: RAD) has moved closer to securing investigational new drug (IND) approval for a cancer-fighting...

Radiopharm Theranostics (ASX: RAD) has boosted its stake in a United States-based joint venture (JV) with the University of Texas MD...

Radiopharm Theranostics (ASX: RAD) has secured the services of United States-based Dr Dimitris Voliotis as its new chief medical officer...

Radiopharm Theranostics (ASX: RAD) has banked US$2 million (AU$3.1 million) from American medical giant Lantheus for the sale of two...

Radiopharm Theranostics (ASX: RAD) has been given the nod of approval by the United States Food and Drug Authority to use its brain...

Radiopharm Theranostics (ASX: RAD) has kicked off the first phase of clinical trials testing its “RAD 204” treatment aimed at beating the...

Radiopharm Theranostics’ (ASX: RAD) stock rocketed up more than 35 per cent this morning after the cancer-fighting firm secured...

Radiopharm Theranostics (ASX: RAD) looks set to fill its coffers with a healthy $18 million following a strategic equity investment and...

The potential for one of Radiopharm Theranostics’ (ASX: RAD) treatments to fight cancer while protecting a patient’s kidneys from...

Radiopharm Theranostics says a new six-patient study shows its terbium-based treatment has superior potential to tackle prostate cancer...

Radiopharm Theranostics says it has dosed its first pancreatic cancer patient in the initial phase of a study aimed at providing doctors...

An immune system protein being developed by Radiopharm Theranostics has for the first time been shown to have the potential to detect and...

Radiopharm Theranostics is poised to open a second site for conducting human trials of its RAD 204 treatment for advanced non-small cell...

Radiopharm Theranostics has stepped closer to kicking off what it says could be a “game-changing” trial for patients with non-small cell...

A research and development (R&D) tax rebate of nearly $5 million from the Australian Government will boost Radiopharm Theranostics’...

Pancreatic cancer patients have been delivered fresh hope following the United States Food and Drug Administration’s decision to clear...